Telephone : +30 210 6597 506
Fax : +30 210 6597 545
e-mail : email@example.com
Dr. Antonia Vlahou received her BS from the School of Biology, University of Athens, Greece and her Ph.D from the Department of Cell Biology, Baylor College of Medicine, Houston Texas. Dr. Vlahou pursued post-doctoral studies at the Eastern VA Medical School, VA, where she was appointed as a Research Assistant Professor from 2001 until 2003 when she moved to the Biomedical Research Foundation of the Academy of Athens (BRFAA). Dr. Vlahou is currently the co-Director of the Proteomics Research Unit at the BRFAA.
During her doctoral and post-doctoral studies Dr. Vlahou received various awards including an award for best oral presentation, Southwestern Developmental Biology Conference, the AFUD/AUA fellowship (1998-2000) as well as the Pfizer Scholar in Urology award (2000). Dr. Vlahou is one of the founding members of the Hellenic Proteomics Society and has served as the General Secretary and President of the Society. She is in the editorial board of J of Proteomics, Proteomics Clinical Applications and PLoS One and has edited one book on clinical proteomics (Methods in Molecular Biology series, Humana Press). She is also the organizer of proteomics courses of 3 masters programs in Athens.
Dr. Vlahou is a highly experienced researcher in the field of clinical proteomics. She has been the Coordinator of the European COST Action on Kidney and Urine Proteomics (EuroKUP) (2008 -2012) and is currently the Coordinator of the Marie Curie ITN program (“Clinical and system –omics for the identification of the Molecular DEterminants of established Chronic Kidney Disease”, iMODE-CKD) και EU FP7 “Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction” (TransBioBC) projects. Since 2010 she serves as external expert for biomarker qualification at the European Medicines Agency (EMA, UK). She is also currently group leader in various EU funded projects (FP7 NeuriNox, SysVasc and Marie Curie EID BCMolMed).
Husi H, Van Agtmael T, Mullen W, Bahlmann FH, Schanstra JP, Vlahou A, Delles C, Perco P, Mischak H. Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in Fatty Acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circ Cardiovasc Genet. 2014;7(2):161-70.
Husi H, Sanchez-Niño MD, Delles C, Mullen W, Vlahou A, Ortiz A, Mischak H.
A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Syst Biol. 2013;7:110.
Frantzi M, Zoidakis J et al and Vlahou A. IMAC fractionation in combination to LC/MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. J of Proteome Research 2013, 12(9):3969-79.
Zoidakis J, Makridakis M, Zerefos PG, et al and Vlahou A. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics 2012 11(4):M111.009449
Vlahou A. Network views for personalized medicine. Proteomics Clin Appl. 2013 ;7(5-6):384-7
Mischak H, Ioannidis JPA, Argiles A, et al and Vlahou A. Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 2012; 42(9):1027-36
Zerefos PG, Aivaliotis M, Baumann M, Vlahou A. Analysis of the urine proteome via a combination of multi-dimensional approaches. Proteomics 2012; 12(3):391-400.
Bitsika V, Roubelakis MG, Zagoura D, et al, Vlahou A, Anagnou NP. Human Amniotic Fluid-Derived Mesenchymal Stem Cells As Therapeutic Vehicles: A Novel Approach For the Treatment of Bladder Cancer. Stem Cells Dev. 2012 21(7):1097-111.
Klein J, Eales J, Zurbig P, Vlahou A, Mischak H, Stevens, R. "Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally-occurring peptide generation" Proteomics, 2013;13(7):1077-82
Vlahou A. Back to the future in bladder cancer research. Expert Rev Proteomics. 2011; 8(3):295-7.
Dakna M, Harris K, Kalousis A, Carpentier S, Kolch W, Schanstra JP, Haubitz M, Vlahou A, Mischak H and Girolami M. Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers. BMC Bioinformatics 2010; 11:594
Mischak H, Allmaier G, Apweiler R, et al and Vlahou A. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010; 2(46):46ps42